Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL94394

BUFEXAMAC
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
CCCCOc1ccc(CC(=O)NO)cc1

Basic Information

ChEMBL ID CHEMBL94394
Name BUFEXAMAC
Phase Approved
Structure Type MOL
InChI Key MXJWRABVEGLYDG-UHFFFAOYSA-N
Therapeutic ✓ Yes

Known Names

Bufexamac Bufexamaco CP 1044 J3 CP-1044-J3 Duradermal NSC-758153 Parfenac
6
Targets
9
Activities
2
Assay Types
0
PK Parameters
20
Publications
7
Known Names
3
Indications
1
Mechanisms

Molecular Properties

223.3
MW (Da)
1.91
ALogP
3
HBA
2
HBD
58.6
PSA (Ų)
0.44
QED
0
Ro5 Violations
6
Rot. Bonds

Drug Information

Molecule Type Small molecule
Availability Withdrawn
Chirality Achiral

Flags

Withdrawn Natural Product
USAN Stem -ac

Extended Properties

Molecular Formula C12H17NO3
MW 223.27
Aromatic Rings 1
Heavy Atoms 16
NP-Likeness -0.61

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Unknown - -

Indications

Arthralgia Myalgia Rheumatic Diseases

ATC Classification

M01AB17
bufexamac
Level 1: MUSCULO-SKELETAL SYSTEM
Level 2: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M02AA09
bufexamac
Level 1: MUSCULO-SKELETAL SYSTEM
Level 2: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

Drug Warnings

Withdrawn
dermatological toxicity
risks of serious skin reactions from bufexamac outweigh any possible benefits when used for the treatment of insect bites, stings and itches, and minor burns and sunburn
Country: European Union; Madagascar; New Zealand   Year: 2010
Withdrawn
immune system toxicity
Contact allergies
Country: European Union; Madagascar; New Zealand   Year: 2010
Withdrawn
immune system toxicity
High risk of sometimes serious contact allergy
Country: European Union; Madagascar; New Zealand   Year: 2010

Activity Summary

IC50 5 meas. best 6.89
Kd 4 meas. best 4.97

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
Polyunsaturated fatty acid 5-lipoxygenase
CHEMBL312
IC50 6.89 5.73 128.8 2
Plasmodium falciparum
CHEMBL364
IC50 5.56 5.56 2771.0 1
Histone deacetylase 6
CHEMBL1865
Kd 4.97 4.97 10700.0 1
Polyamine deacetylase HDAC10
CHEMBL5103
Kd 4.91 4.91 12300.0 1
Arachidonate 5-lipoxygenase
CHEMBL2980
IC50 4.46 4.46 35000.0 1
Aminopeptidase N
CHEMBL4117
IC50 4.09 4.09 81200.0 1

Activity Data Samples

Top measurements by pChEMBL value

Literature References

PubMed DOI Target Context # Activities
2308149 10.1021/jm00165a017 Polyunsaturated fatty acid 5-lipoxygenase 2
37468498 10.1038/s41467-023-40064-9 Thromboxane A2 receptor 2
37468498 10.1038/s41467-023-40064-9 Prostaglandin G/H synthase 1 2
- 10.6019/CHEMBL4808148 Histone deacetylase 6 2
- 10.6019/CHEMBL4651402 SARS-CoV-2 2
- 10.6019/CHEMBL4495565 SARS-CoV-2 2
37468498 10.1038/s41467-023-40064-9 Alpha-1A adrenergic receptor 2
37468498 10.1038/s41467-023-40064-9 Muscarinic acetylcholine receptor M1 2
9276024 10.1021/jm9701785 HaCaT 2
23627282 10.1021/jm4001659 Histone deacetylase 3 1
23627282 10.1021/jm4001659 Histone deacetylase 2 1
23627282 10.1021/jm4001659 Polyamine deacetylase HDAC10 1
23571415 10.1124/mol.112.084152 Solute carrier organic anion transporter family member 1B1 1
23571415 10.1124/mol.112.084152 Solute carrier organic anion transporter family member 1B3 1
- 10.1101/2020.04.03.023846 SARS-CoV-2 1
- 10.21203/rs.3.rs-23951/v1 SARS-CoV-2 1
- 10.6019/CHEMBL4495564 Replicase polyprotein 1ab 1
23627282 10.1021/jm4001659 Histone deacetylase 8 1
20547797 10.1128/aac.00431-10 Plasmodium falciparum 1
38318365 10.1016/j.isci.2024.108907 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 1

Data from ChEMBL 36 via Core Engine